TY - JOUR
T1 - Flow Cytometric Immune Profiling in Infliximab-Associated Tuberculosis
AU - Pennington, Kelly
AU - Sasieta, Humberto C.
AU - Ramos, Guiherme P.
AU - Erskine, Courtney L.
AU - Van Keulen, Virginia P.
AU - Peikert, Tobias
AU - Escalante, Patricio
N1 - Funding Information:
FundIng: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by internal Mayo Clinic grants (The 2009 and 2011 Lucille Nelson Clinical Career Development Award in Pulmonary Research; the 2011 Mayo Clinic Center for Clinical and Translational Sciences (CCaTS) Career Transition Award; the 2012 Mayo Clinic CCaTS Novel Methodology Award; the 2014 Mayo Clinic Department of Medicine Career Development Time for Scholarly Physicians Award; and the 2010 Clinical Immunology and Immunotherapeutics Program Award (P.E.). This research was also supported by K23CA159391 (T.P.). Part of this project was also supported by Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS). This paper’s contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or Mayo Clinic. No other financial or material support for this work was provided to the authors and participants.
Publisher Copyright:
© 2017, © The Author(s) 2017.
PY - 2017/8/7
Y1 - 2017/8/7
N2 - Tumor necrosis factor α antagonists are increasingly used to treat inflammatory and autoimmune disorders and are associated with increased risk of active tuberculosis. Diagnosis of active tuberculosis in patients taking tumor necrosis factor α antagonists can be challenging owing to increased incidence of extrapulmonary manifestations and false-negative results on current available diagnostic tests. We present a case of a young woman on infliximab for ulcerative colitis who presented with disseminated tuberculosis. As part of a research study, we performed flow cytometric immune profiling, which has previously not been reported in patients with active tuberculosis taking tumor necrosis α antagonists. The flow cytometry results were within the positive thresholds for tuberculosis infection. Flow cytometric immune profiling may be a valid diagnostic tool for patients taking tumor necrosis factor α antagonists.
AB - Tumor necrosis factor α antagonists are increasingly used to treat inflammatory and autoimmune disorders and are associated with increased risk of active tuberculosis. Diagnosis of active tuberculosis in patients taking tumor necrosis factor α antagonists can be challenging owing to increased incidence of extrapulmonary manifestations and false-negative results on current available diagnostic tests. We present a case of a young woman on infliximab for ulcerative colitis who presented with disseminated tuberculosis. As part of a research study, we performed flow cytometric immune profiling, which has previously not been reported in patients with active tuberculosis taking tumor necrosis α antagonists. The flow cytometry results were within the positive thresholds for tuberculosis infection. Flow cytometric immune profiling may be a valid diagnostic tool for patients taking tumor necrosis factor α antagonists.
KW - Tumor necrosis factor alpha antagonists
KW - active tuberculosis
KW - flow cytometry
KW - inflammatory bowel disease
UR - http://www.scopus.com/inward/record.url?scp=85031746208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031746208&partnerID=8YFLogxK
U2 - 10.1177/1179547617724776
DO - 10.1177/1179547617724776
M3 - Article
AN - SCOPUS:85031746208
SN - 1179-5476
VL - 10
SP - 1
EP - 3
JO - Clinical Medicine Insights: Case Reports
JF - Clinical Medicine Insights: Case Reports
ER -